Y-mabs receives priority review status for cancer drug in China

A potential launch of Y-mabs's drug Danyelza is one step closer after being granted priority review status, ensuring a faster assessment by the Chinese authorities.

Photo: Thomas Peter/Reuters/Ritzau Scanpix

In a collaboration with the partner Schiclone Pharmaceuticals, biopharmaceutical company Y-mabs has been granted priority review by China's National Medical Products Administration (NMPA).

The drug Danyelza, which has received the special status, is for the treatment of neuroblastoma in the bone or bone marrow. The cancer develops in nerve tissue in infants and children. In the US, the drug was approved and fast-tracked by the FDA under the accelerated approval program.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs